+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Raynauds Disease - Pipeline Review, H1 2017

  • ID: 4115142
  • Report
  • March 2017
  • 49 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Apricus Biosciences Inc
  • Covis Pharmaceuticals Inc
  • MORE
Raynauds Disease - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Raynauds Disease - Pipeline Review, H1 2017, provides an overview of the Raynauds Disease (Cardiovascular) pipeline landscape.

Raynauds disease is a common condition that affects the blood supply to certain parts of the body, usually the fingers and toes. Predisposing factors include age, gender, family history and smoking. Symptoms include fingers, toes, ears, or nose to become white, and then turn blue. Treatment includes vasodilator, alpha blockers and calcium channel blockers.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Raynauds Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Raynauds Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Raynauds Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Raynauds Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively. Similarly, the Universities portfolio in Unknown stages comprises 1 molecules, respectively.

Raynauds Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Raynauds Disease (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Raynauds Disease (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Raynauds Disease (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Raynauds Disease (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Raynauds Disease (Cardiovascular)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Raynauds Disease (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Raynauds Disease (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Apricus Biosciences Inc
  • Covis Pharmaceuticals Inc
  • MORE
Introduction

Raynauds Disease - Overview

Raynauds Disease - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Raynauds Disease - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Raynauds Disease - Companies Involved in Therapeutics Development

Allergan Plc

Apricus Biosciences Inc

Covis Pharmaceuticals Inc

Human Stem Cells Institute

Raynauds Disease - Drug Profiles

alprostadil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Block TRPM8 for Raynauds Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ELS-140 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neovasculgen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nitroglycerin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Raynauds Disease - Dormant Projects

Raynauds Disease - Discontinued Products

Raynauds Disease - Product Development Milestones

Featured News & Press Releases

Mar 08, 2016: Apricus Biosciences to Present at the 28th Annual ROTH Conference

Feb 02, 2016: Apricus Biosciences to Present at the 18th Annual BIO CEO & Investor Conference, Provide Update on Vitaros

Aug 05, 2015: Apricus Biosciences to Provide Update On The European Launch of Vitaros at the Canaccord Genuity 35th Annual Growth Conference

Apr 28, 2015: Apricus Biosciences to Present at Two Investor Conferences in May

Jan 27, 2015: Apricus Biosciences Announces Issuance of U.S. Patent for RayVa

Dec 04, 2014: Apricus Biosciences Announces First Patient Enrolled In Phase 2a Clinical Trial For RayVa In Patients With Raynaud's Phenomenon

Oct 13, 2014: Apricus Biosciences Announces Notice of Allowance of U.S. Patent Application for RayVa

Oct 01, 2014: Apricus Biosciences to Present at the 13th Annual BIO Investor Forum

May 12, 2014: Apricus Biosciences Receives FDA Clearance to Begin Clinical Trial of RayVa for Secondary Raynaud's Phenomenon

Dec 13, 2012: MediQuest Therapeutics To Conduct Meetings At J.P. Morgan Conference Regarding Phase III Topical Formulation Vascana

May 31, 2011: Apricus Bio Receives Israeli Patent For RayVa For Raynaud's Phenomenon

Apr 13, 2011: Apricus Bio Files For Orphan Drug Designation For RayVa

Sep 22, 2010: FDA Guides Apricus Bio On RayVa's Approvability For Raynaud's Syndrome Secondary To Scleroderma

Jan 10, 2006: MediQuest Therapeutics Receives Special Protocol Assessment From The U.S. FDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Raynauds Disease, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Raynauds Disease - Pipeline by Allergan Plc, H1

Raynauds Disease - Pipeline by Apricus Biosciences Inc, H1

Raynauds Disease - Pipeline by Covis Pharmaceuticals Inc, H1

Raynauds Disease - Pipeline by Human Stem Cells Institute, H1

Raynauds Disease - Dormant Projects, H1

Raynauds Disease - Discontinued Products, H1

List of Figures:

Number of Products under Development for Raynauds Disease, H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
4 of 5
  • Allergan Plc
  • Apricus Biosciences Inc
  • Covis Pharmaceuticals Inc
  • Human Stem Cells Institute
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll